384 related articles for article (PubMed ID: 28829399)
1. Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
[TBL] [Abstract][Full Text] [Related]
2. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Gland Malignancies.
Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
[TBL] [Abstract][Full Text] [Related]
6. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Filetti S; Durante C; Hartl D; Leboulleux S; Locati LD; Newbold K; Papotti MG; Berruti A;
Ann Oncol; 2019 Dec; 30(12):1856-1883. PubMed ID: 31549998
[No Abstract] [Full Text] [Related]
7. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
9. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
10. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
11. Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.
Ilanchezhian M; Khan S; Okafor C; Glod J; Del Rivero J
Horm Metab Res; 2020 Aug; 52(8):588-597. PubMed ID: 32299110
[TBL] [Abstract][Full Text] [Related]
12. Well-differentiated carcinoma of the thyroid.
Boone RT; Fan CY; Hanna EY
Otolaryngol Clin North Am; 2003 Feb; 36(1):73-90, viii. PubMed ID: 12803010
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and diagnostic significance of noninvasive follicular thyroid neoplasm with papillary-like nuclear features among tumors previously diagnosed as follicular adenoma: a single-institutional study in Japan.
Hirokawa M; Higuchi M; Suzuki A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2020 Oct; 67(10):1071-1075. PubMed ID: 32595200
[TBL] [Abstract][Full Text] [Related]
14. Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A; Borges de Souza P; Censi S; Muzza M; Nucci N; Sponziello M
Front Endocrinol (Lausanne); 2020; 11():102. PubMed ID: 32231639
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Xu B; Tallini G; Scognamiglio T; Roman BR; Tuttle RM; Ghossein RA
Thyroid; 2017 Apr; 27(4):512-517. PubMed ID: 28136139
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
17. Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B; Menhart K; Hellwig D; Grosse J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629126
[TBL] [Abstract][Full Text] [Related]
18. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
19. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
